Shopping Cart
- Remove All
- Your shopping cart is currently empty
IDH-305 is an orally available, mutation-selective, and brain-penetrant IDH1 inhibitor targeting the IDH1 (R132) mutation. It is 200-fold more selective for mutant IDH1 isoforms than wild type, with IC50s of 27 nM, 28 nM, and 6.14 nM for IDH1R132H, IDH1R132C, and IDH1WT, respectively.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $52 | In Stock | |
5 mg | $128 | In Stock | |
10 mg | $178 | In Stock | |
25 mg | $369 | In Stock | |
50 mg | $558 | In Stock | |
1 mL x 10 mM (in DMSO) | $139 | In Stock |
Description | IDH-305 is an orally available, mutation-selective, and brain-penetrant IDH1 inhibitor targeting the IDH1 (R132) mutation. It is 200-fold more selective for mutant IDH1 isoforms than wild type, with IC50s of 27 nM, 28 nM, and 6.14 nM for IDH1R132H, IDH1R132C, and IDH1WT, respectively. |
Targets&IC50 | IDH1 (R132C):28 nM, IDH1 (R132H):27 nM, IDH1 (WT):6.14 μM |
In vitro | IDH-305 suppresses HCT116-IDH1R132H /- cells (IC50 of 24 nM)[1]. |
In vivo | P.o. administration of 30-300 mg/kg IDH-305 twice daily for 21 days suppresses 2-HG production and 2-HG-dependent tumor growth of an IDH1 mutant PDX melanoma model [1]. |
Molecular Weight | 490.45 |
Formula | C23H22F4N6O2 |
Cas No. | 1628805-46-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (203.90 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.